GlassScriptPhysician profile
Richard Y Ha
NPI 1609849207
$16,878.19
in general payments reported to CMS, 2019-2025
17 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $970 · 2021: $1,296 · 2022: $1,111 · 2023: $657 · 2024: $256 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Synthes Gmbh | $6,664.26 | 2019 | |
| Sientra, INC. | $3,271.97 | 2019-2021 | |
| Kls-Martin L.P. | $2,679.64 | 2019-2025 | |
| Allergan, INC. | $888.51 | 2019-2022 | |
| Mentor Worldwide LLC | $836.91 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Depuy Synthes Sales INC. | $633.73 | 2021-2025 | Na, Trumatch, Matrixmidface |
| Tepha INC | $605.98 | 2019-2020 | |
| Musculoskeletal Transplant Foundation INC. | $461.66 | 2019-2024 | |
| Bard Peripheral Vascular, INC. | $249.01 | 2021 | |
| Tela Bio, INC. | $175.00 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Davol INC. | $151.85 | 2022 | |
| Merz North America, INC. | $118.33 | 2020-2021 | |
| Abbvie INC. | $65.46 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $33.42 | 2019 | |
| Smith+Nephew, INC. | $26.62 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $15.84 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Ha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.